FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to peptides-coagonists of glucose-dependent insulinotropic peptide/glucagon-like peptide-1 (hereinafter – GIP/GLP-1); it can be used in medicine to obtain a drug for the treatment or prevention of Alzheimer’s disease or Parkinson’s disease. Peptides are obtained $$$ , $$$ , where X = aminoisobutyric acid. Additionally, peptides can be covalently bound to a hydrophilic fragment.
EFFECT: invention provides for the production of GIP/GLP-1 coagonists with enhanced neuroprotective properties compared to individual analogues of GLP-1 and GIP in animal models of Alzheimer’s and Parkinson’s disease.
27 cl, 12 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| COMPOSITIONS AND METHODS FOR CONTROLLING ACCUMULATION OF ADIPOSE TISSUE | 2014 |
|
RU2711478C2 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY | 2008 |
|
RU2523894C2 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
